LIVZON PHARMA (01513) Appoints Xia Yu as Company's Securities Affairs Representative

Like
Comment
Favorite

LIVZON PHARMA (01513) Appoints Xia Yu as Company's Securities Affairs Representative

Stock News12-30 18:58

LIVZON PHARMA (01513) announced that the board of directors of Livzon Pharmaceutical Group Co., Ltd. recently received the resignation letter from the company's Securities Affairs Representative, Ms. Li Xiaoyu. Due to personal reasons, Ms. Li Xiaoyu resigned from her position as the company's Securities Affairs Representative. The resignation became effective from the date the letter was delivered to the board, and she will no longer hold any position within the company following her departure.

On December 30, 2025, the company convened its 31st meeting of the 11th Board of Directors. During the meeting, the "Proposal on Appointing the Company's Securities Affairs Representative" was reviewed and approved. The board agreed to appoint Ms. Xia Yu as the company's Securities Affairs Representative, who will assist the Board Secretary in fulfilling relevant duties.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1113128497?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-30 18:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113128497","market":"nz","top_or_hot":-1,"title":"LIVZON PHARMA (01513) Appoints Xia Yu as Company's Securities Affairs Representative","media":"Stock News","content":"<p>LIVZON PHARMA (01513) announced that the board of directors of Livzon Pharmaceutical Group Co., Ltd. recently received the resignation letter from the company's Securities Affairs Representative, Ms. Li Xiaoyu. Due to personal reasons, Ms. Li Xiaoyu resigned from her position as the company's Securities Affairs Representative. The resignation became effective from the date the letter was delivered to the board, and she will no longer hold any position within the company following her departure.</p>\n<p>On December 30, 2025, the company convened its 31st meeting of the 11th Board of Directors. During the meeting, the \"Proposal on Appointing the Company's Securities Affairs Representative\" was reviewed and approved. The board agreed to appoint Ms. Xia Yu as the company's Securities Affairs Representative, who will assist the Board Secretary in fulfilling relevant duties.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LIVZON PHARMA (01513) Appoints Xia Yu as Company's Securities Affairs Representative</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLIVZON PHARMA (01513) Appoints Xia Yu as Company's Securities Affairs Representative\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-30 18:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LIVZON PHARMA (01513) announced that the board of directors of Livzon Pharmaceutical Group Co., Ltd. recently received the resignation letter from the company's Securities Affairs Representative, Ms. Li Xiaoyu. Due to personal reasons, Ms. Li Xiaoyu resigned from her position as the company's Securities Affairs Representative. The resignation became effective from the date the letter was delivered to the board, and she will no longer hold any position within the company following her departure.</p>\n<p>On December 30, 2025, the company convened its 31st meeting of the 11th Board of Directors. During the meeting, the \"Proposal on Appointing the Company's Securities Affairs Representative\" was reviewed and approved. The board agreed to appoint Ms. Xia Yu as the company's Securities Affairs Representative, who will assist the Board Secretary in fulfilling relevant duties.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"161027","symbol_name":"证券","start_time":0,"source_url":"","article_id":"1113128497","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113128497","pubTimestamp":1767092298,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"LIVZON PHARMA (01513) announced that the board of directors of Livzon Pharmaceutical Group Co., Ltd. recently received the resignation letter from the company's Securities Affairs Representative, Ms....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"161027":"证券","01513":"丽珠医药","BK1191":"制药"},"translate_title":"丽珠医药(01513)委任夏雨为公司证券事务代表","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161027":1,"01513":1},"content_text":"LIVZON PHARMA (01513) announced that the board of directors of Livzon Pharmaceutical Group Co., Ltd. recently received the resignation letter from the company's Securities Affairs Representative, Ms. Li Xiaoyu. Due to personal reasons, Ms. Li Xiaoyu resigned from her position as the company's Securities Affairs Representative. The resignation became effective from the date the letter was delivered to the board, and she will no longer hold any position within the company following her departure.\nOn December 30, 2025, the company convened its 31st meeting of the 11th Board of Directors. During the meeting, the \"Proposal on Appointing the Company's Securities Affairs Representative\" was reviewed and approved. The board agreed to appoint Ms. Xia Yu as the company's Securities Affairs Representative, who will assist the Board Secretary in fulfilling relevant duties.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}